The 24 references in paper R. Kazakov E., V. Evteev A., O. Muslimova V., I. Mazerkina A., E. Demchenkova Yu., E. Shikh V., Р. Казаков Е., В. Евтеев А., О. Муслимова В., И. Мазеркина А., Е. Демченкова Ю., Е. Ших В. (2018) “Перспективы использования полиморфизма C3435T гена P-гликопротеина ABCB1 в персонализированной медицине // Prospects of using C3435T polymorphism in the ABCB1 gene encoding P-glycoprotein in personalised medicine” / spz:neicon:vedomostincesmp:y:2017:i:4:p:212-220

1
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: from genomics to mechanism. Oncogene 2003; 22(47): 7468–85.
(check this in PDF content)
2
Kroetz DL, Pauli-Magnus C, Hodges LM, Huang CC, Kawamoto M, Johns SJ, et al. Sequence diversity and haplotype structure in the humanABCB1(MDR1, multidrug resistance transporter) gene. Pharmacogenetics 2003; 13(8): 481–94.
(check this in PDF content)
3
Takane H, Kobayashi D, Hirota T, Kigawa J, Terakawa N, Otsubo K, et al. Haplotype-oriented genetic analysis and functional assessment of promoter variants in theMDR1(ABCB1) gene. J Pharmacol Exp Ther. 2004; 311(3): 1179–87.
(check this in PDF content)
4
Romanov BK. Regulation of myocardial lysosomal enzyme activity by calcium. Biomedical Chemistry 2005; 51(6): 634–42 (in Russian).
(check this in PDF content)
5
Li Y, Wang Y, Sun J, Li Y, Yang L. Distribution of the functionalMDR1 C3435T polymorphism in the Han population of China. Swiss Med Wkly. 2006; 136(23–24): 377–82.
(check this in PDF content)
6
Takara K, Takagi K, Tsujimoto M, Ohnishi N, Yokoyama T. Digoxin up-regulates multidrug resistance transporter (MDR1) mRNA and simultaneouslydown-regulatessteroidxenobioticreceptor mRNA. Biochem Biophys Res Commun. 2003; 306(1): 116–20.
(check this in PDF content)
7
Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97(7): 3473–8.
(check this in PDF content)
8
Chowbay B, Li H, David M, Cheung YB, Lee EJ. Meta-analysis of the influence ofMDR1C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression. Br J Clin Pharmacol. 2005; 60(2): 159–71.
(check this in PDF content)
9
Sychev DA, Ignatiev IV, Andreev DA, Poshukaeva LG, Kolkhir PV, Zhukova EE, et al. Glycoprotein P pharmacogenetic assessment role in digoxin pharmacotherapy individualization: a new approach for an old problem. Russian Journal of Cardiology 2006; (4): 64–8 (in Russian).
(check this in PDF content)
10
Drozdzik M, Rudas T, Pawlik A, Kurzawski M, Czerny B, Gornik W, et al. The effect of 3435C>TMDR1gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur J Clin Pharmacol. 2006; 62(11): 933–7.
(check this in PDF content)
11
Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, et al.MDR1gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br J Clin Pharmacol. 2002; 53(5): 526–34.
(check this in PDF content)
12
Yi SY, Hong KS, Lim HS, Chung JY, Oh DS, Kim JR, et al. A variant 2677A allele of theMDR1gene affects fexofenadine disposition. Clin Pharmacol Ther. 2004; 76(5): 418–27.
(check this in PDF content)
13
Goreva OB, Grishanova AY, Mukhin OV, Domnikova NP, Lyakhovich VV. Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based onMDR1gene G2677T and C3435T polymorphisms. Bull Exp Biol Med. 2003; 136(2): 183–5.
(check this in PDF content)
14
Yamauchi A, Ieiri I, Kataoka Y, Tanabe M, Nishizaki T, Oishi R, et al. Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of theABCB1(MDR1) gene. Transplantation 2002; 74(4): 571–2.
(check this in PDF content)
15
Goto M, Masuda S, Saito H, Uemoto S, Kiuchi T, Tanaka K, et al. C3435T polymorphism in theMDR1gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12(6): 451–7.
(check this in PDF content)
16
Marzolini C, Paus E, Buclin T, Kim RB. Polymorphisms in human MDR1(P-glycoprotein): Recent advances and clinical relevance. Clin Pharmacol Ther. 2004; 75(1): 13–33.
(check this in PDF content)
17
Skarke C, Jarrar M, Schmidt H, Kauert G, Langer M, Geisslinger G, et al. Effects ofABCB1(multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers. Pharmacogenetics 2003; 13(11): 651–60.
(check this in PDF content)
18
Pauli-Magnus C, Feiner J, Brett C, Lin E, Kroetz DL. No effect of MDR1C3435T variant on loperamide disposition and central nervous system effects. Clin Pharmacol Ther. 2003; 74(5): 487–98.
(check this in PDF content)
19
Kim KA, Park PW, Park JY. Effect ofABCB1(MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol. 2007; 63(1): 53–8.
(check this in PDF content)
20
Zuo XC, Zhang WL, Yuan H, Barrett JS, Hua Y, Huang ZJ, et al.ABCB1 polymorphism and gender affect the pharmacokinetics of amlodipine in Chinese patients with essential hypertension: a population analysis. Drug Metab Pharmacokinet. 2014; 29(4): 305–11.
(check this in PDF content)
21
Semenov AV, Sychev DA, Kukes VG. Effect of genesSLCO1B1and MDR1polymorphism on atorvastatin pharmacokinetics and pharmacodynamics in patients with primary hypercholesterolemia: results of pilot pharmacogenetics study. Rational Pharmacother Card. 2008; (2): 47–50 (in Russian).
(check this in PDF content)
22
Su J, Xu H, Yang J, Yu Q, Yang S, Zhang J, et al.ABCB1C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysis. Lipids Health Dis. 2015; 14: 122.
(check this in PDF content)
23
McBride BF, Yang T, Roden DM. Influence of the G2677T/C3435T haplotype ofMDR1on P-glycoprotein trafficking and ibutilide-induced block of HERG. Pharmacogenomics J. 2009; 9(3): 194–201.
(check this in PDF content)
24
Sokova EA. Monitoring post-approvial drug safety in pregnancy: pharmacogenetic aspects. Safety and Risk of Pharmacotherapy 2015; (3): 30–5 (in Russian). AUTHORS Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» of the Ministry of Health
(check this in PDF content)